

PRELIMINARY PROGRAMME



isirv

International Society for
Influenza and other
Respiratory Virus Diseases

Immunological Assays and Correlates of Protection for Next Generation Influenza Vaccines

31 March – 2 April 2019 Siena | Italy

Day 1 Sunday 31 March

12:30 Registration / Poster Mounting

14:30 **Welcome and Opening Remarks** (Co-Chairs) **Rebecca Cox & Emanuele Montomoli**

14:45 **Session A Keynote Presentations**

Influenza immunity and knowledge gaps

Overview of next generation 'universal' influenza vaccines

Jackie Katz CDC, USA

Florian Krammer

Icahn School of Medicine at Mount Sinai, USA

16:15 **BREAK**

16:45	Session B Immune Correlates of Protection in Humans	
	Correlates of Protection History of human challenge systems Experience with human challenge studies to assess vaccine strategies (LAIV)	Rebecca Cox University of Bergen, Norway Bruce Innis PATH, USA John Treanor University of Rochester Medical Center, USA
18:30 WELCOME RECEPTION		
Day 2 Monday 1 April		
09:00	Session C Cohorts and Systems to Define Immune Correlates of Protection in Humans	
	Systems immunology approaches to influenza Cohort studies Longitudinal cohorts to inform on influenza immunity and correlates	Bali Pulendran Stanford University, USA Aubree Gordon University of Michigan, USA Nancy Leung University of Hong Kong, China
10:30 BREAK		
11:00	Session D Predicting Vaccine Performance	
	Measuring Vaccine Effectiveness and Correlates of Protection Studies in paediatric populations Prime boosting studies	Arnold Monto University of Michigan, USA Kanta Subbarao WHO Collaborating Centre for Reference and Research on Influenza, Australia
12:30 LUNCH		

14:00	Session E Demonstration of Protection in Animal Models	
	From mice to non-human primates Ferret Model Transfer models of immune effectors	Yoshihiro Kawaoka University of Wisconsin, USA Stacey Schultz-Cherry St Jude's, USA Pierre Bruhns Institut Pasteur, France
15:30	BREAK	
16:00	Session F Serology	
	Serological assays (HI, VN and M2) Stalk based antibodies NA assays and standardisation Local antibody assays/ novel sampling methods Antibody Dependent Cell-mediated Cytotoxicity Assays	Min Levine CDC, USA Raffael Nachbagauer Icahn School of Medicine at Mount Sinai, USA Maryna Eichelberger FDA, USA Katja Hoschler Public Health England, UK Stephen Kent Doherty Institute, Australia
17:30-19:30	POSTER SESSION	

DAY 3 Tuesday 2 April

09:00	Session G	
	Assays for B and T cells B cell immunity to influenza & B cellular assays T cell immunity to influenza & T cellular assays	Ali Ellebedy Washington University School of Medicine, St Louis, USA Katherine Kedzierska Doherty Institute, Australia

	Assay Standardisation / Harmonisation Standardisation of HA and NA assays Standardisation of T cellular assays for influenza Statistical Approaches	Othmar Engelhardt National Institute for Biological Standards and Control, UK Frédéric Clement Ghent University, Belgium Lingyi Zheng Sanofi Pasteur, USA
11:00	BREAK	
11:30	Session H Recap of Sessions B-E Group discussion – The Way Forward	
	Towards identifying correlates of protection and developing consensus on immune responses to target Identify collaborative studies/strategies to identify correlates	
12:30	LUNCH	
14:00	Session I Oral Abstracts (2 hours)	
16:00	BREAK	
16:30	Session J Recap of Sessions F-H Group discussion – The Way Forward II	
	In developing and standardising assays needed for measuring the relevant immune responses of next generation vaccines. What are relevant immune responses? Best assays available Approaches to standardisation and harmonisation	
17:30	Closing remarks – end of meeting	